DOSSIER · 13F-HR · Q3 2025

TAKEDA PHARMACEUTICAL CO LTD

$16M in tracked AUM across 9 positions as of Q3 2025.

TP
CIK 0001395064 · last filed Sep 30, 2025
Total AUM
$16M
as of Q3 2025
Holdings
9
positions
Whale Score
56
56
tracked
Activity
no data
changes this Q
AI Analysis · Q3 2025

TAKEDA PHARMACEUTICAL CO LTD filed its latest 13F-HR for Q3 2025. See the latest holdings and position changes below.

Quarter at a glance — Q3 2025

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q3 2025.

#HoldingValueSharesWeight
01
OVID
Ovid Therapeutics, Inc.
$10M7.5M59.8%
02
EQ
Equillium, Inc.
$3M1.8M15.9%
03
XLO
Xilio Therapeutics, Inc. (formerly Akrevia Therapeutics)
$1M1.5M7.6%
04
STTK
Shattuck Labs, Inc.
$1M516K7.5%
05
55083R104
Lyell Immunopharma, Inc.
$891K55K5.4%
06
AMWL
American Well Corporation
$478K78K2.9%
07
RANI
Rani Therapeutics Holdings, Inc.
$102K203K0.6%
08
LAB
Standard Biotools, Inc.
$21K17K0.1%

Filing history

2025Q3Sep 30
$16M 16.3%
9 positionsView →
2025Q2Jun 30
$20M 43.9%
12 positionsLocked
2025Q1Mar 31
$14M 48.8%
9 positionsLocked
2024Q4Dec 31
$27M 30.0%
12 positionsLocked
2024Q3Sep 30
$38M 83.7%
12 positionsLocked
2024Q2Jun 30
$232M 19.6%
15 positionsLocked
2024Q1Mar 31
$289M 11.7%
17 positionsLocked
2023Q4Dec 31
$327M
16 positionsLocked